News | Radiation Therapy | February 04, 2021

GenesisCare Brings Florida Cancer Patients First-of-its-Kind Ethos Adaptive Intelligence Technology

Linac radiotherapy will treat cancer more accurately than conventional therapy and reduces damage to healthy tissue

 GenesisCare — one of the leading oncology providers in the United States, Australia, Spain, and the United Kingdom — announced the addition of a game-changing adaptive therapy, the Ethos.

February 4, 2021 —  GenesisCare — one of the leading oncology providers in the United States, Australia, Spain, and the United Kingdom — announced the addition of a game-changing adaptive therapy, the Ethos. Designed to create customized cancer-fighting treatments, this technology targets tumors as the body changes and cancer shrinks. Personalized patient care is one of GenesisCare's commitments to the community and this treatment helps put the patient at the center of care. The combination of technology and treatments allows oncologists to quickly adapt treatment plans based on their ability to view daily changes in the patient's anatomy. What used to take two-three days now takes 15-minutes.

"Ethos is one of the most unique and impactful technology tools for taking action against cancer because it allows up-to-the-moment changes in radiation delivery calculations, so we maximize the cure rate while minimizing any side effects to healthy tissue," said Timothy Kerwin, M.D.,, Radiation Oncology Specialist for GenesisCare.

As we approach Cancer Awareness Month (February) and see patient numbers presenting with late-stage cancer rise due to delayed testing/treatment during COVID, this new technology is just in time to raise the bar in cancer treatment. Nearly a years-worth of pandemic interrupted lives has shown an increase of late state cancer by 20% on average in the U.S. and 27% in the U.K. means this technology is the game-changer doctors and patients need to make a positive impact on treatment outcomes. With trends showing an increased risk of mortality for breast, lung, and pancreatic cancer between 1.2 to 3.2 percent and a decrease in survival for each day treatment is delayed beyond nine weeks, the need for powerful radiotherapy like Ethos is now.

This comprehensive technology better targets tumors by monitoring and modifying treatment based on specific patient needs throughout the cancer care process. Radiation doses are now reduced to healthy tissue and organs, improving overall outcomes.

GenesisCare patient Michael Harms, diagnosed with prostate cancer in October 2020, completed 43 days of scanning in record time right before Christmas. "I feel lucky to have access to customized radiation plans that targeted my cancer using advanced-scanning technology located close to my home," said Harms.

"No one else in Florida is offering this adaptive therapy technology. It is a privilege to be the first cancer center in Florida, and one of the first nationwide, to offer this advancement to our patients," stated Kerwin. "The addition of this technology is a testament to GenesisCare's commitment to delivering an elite level of care that has no bounds."

As a leading provider of oncology services globally, GenesisCare strives to ensure its patients' best possible life outcomes by bridging the gap between integrated cancer care, research and development, and medical technology. With its origins in radiation oncology, GenesisCare has, in recent years, expanded its services to include medical oncology, urology, and a cutting-edge form of nuclear medicine.

For more information: www.genesiscare.com

Related Content

F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.

F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.

News | Molecular Imaging | February 22, 2021
February 22, 2021 — Molecular imaging
Radiology, radiation therapy, PACS, Enterprise image, X-ray, DR Systems, CT, MRI, contrast, ultrasound, VNA, product comparisons, comparison charts on ITN magazine.
Feature | February 17, 2021
Imaging Technology News (ITN) maintains more than 40
Immunotherapy-based precision medicine clinical trials being developed

Getty Images

News | Prostate Cancer | February 16, 2021
February 16, 2021 — Black men die more often of prostate cancer yet, paradoxically, have greater survival benefits fr

Chart courtesy of the American Cancer Society

News | Breast Imaging | February 08, 2021
February 8, 2021 — Cancer ranks as a leading cause of death in every country in the world, and, for the first time,
Phase III clinical trial of men with a clinical suspicion of prostate cancer finds MRI with targeted biopsies to be more accurate at diagnosis and less intrusive than current standard
News | Magnetic Resonance Imaging (MRI) | February 08, 2021
February 8, 2021 — The results of a Phase III randomized clinical trial have shown that when it comes to detecting cl

Images in 69-year-old man with biopsy-confirmed Gleason score 7 (3+4) prostate cancer. (a) Pretreatment axial T2-weighted fast spin-echo MRI scan (repetition time msec/echo time msec, 3820/97) shows tumor in midline anterior transition zone (arrow). (b) Intraoperative MRI scan shows contoured rectal wall (red line), prostate margin (blue outline), and region of interest (orange outline). Because the urethra was included in planned treatment volume, a suprapubic catheter was placed for continuous bladder drainage during treatment. (c) Intraoperative MRI scan shows focused ultrasound beam path (blue) overlaid on treatment plan. Rectangles illustrate each sonication spot. (d) Thermal map image obtained during treatment with heat deposition color coded in red overlaid on sonication spot. (e) Axial gadopentetate dimeglumine-enhanced MRI scan (230/2.97) obtained immediately after treatment shows devascularized ablated volume (arrows). (f) Corresponding T2-weighted fast spin-echo MRI scan (3820/97) at 5 months after ablation shows complete involution of transition zone. All seven cores from treatment area margins were negative for cancer at biopsy. Image courtesy of the Radiological Society of North America

News | Prostate Cancer | February 05, 2021
February 5, 2021 — A technique that delivers...
Real Time Imaging Technologies LLC iannounced that it has received U.S. Patent No. 10,898,070 IMAGING APPARATUS AND METHODS which covers the company’s methods for incorporating microlens into X-ray imaging detectors that enables significantly lower radiation dose without compromising image resolution.

Getty Images

News | Radiation Dose Management | February 05, 2021
February 5, 2021 —